Rapid Nexus has developed an advanced wound care healing system that will address the global burden of chronic wounds, associated infection, and amputation. Our system Hemastyl R ™ and Gen-ray ™ LED combination system has successfully treated 22 patients to date, successfully reversing necrosis, closed open chronic wounds, grown tissue and re-established circulation. We are not only pioneering wound healing by focusing on restoration of voltage flow in every layer of the tissue, but we are also changing and saving lives. We operate in a complex market of chronic disease such as diabetes, with complications and comorbidities leading to vast, unnecessary cost on the purse of healthcare insurers and providers. We are in the process of FDA Breakthrough Devices Designation and have pilot studies in UT, UC Texas, and Australia. Rapid Nexus, led by physician Dr. Margaret Kalmeta, has raised $1.3m to date, has 6 patent applications, has an experienced management team and board with many significant exits.
Systems Oncology is an AI powered data-driven biopharmaceutical company. We use a proprietary artificial intelligence-based platform that drives discovery and development of cancer therapies. We use Our Expansive.AI™ computational platform for mining genomic evolution and multi-target discovery. SO has successfully out-licensed multiple programs to Pharma, and we currently have 35 wholly-owned projects in oncology indications, with 4 programs ready for out-licensing in 2021. One program in particular, MyxSO, has compelling data that we are very excited about. For some background, MyxSO is a pan cancer, pre-clinic dual armed oncolytic virus IO therapy that has tremendous market potential. Dr. Dan Von Hoff, our Chief Clinical Strategist, has designed a very efficient clinical trial strategy that should lead to rapid regulatory approval. We are looking to form a collaboration or joint venture to partner the MyxSO program and drive its development into the clinic.
Thrive is commercializing a family of instruments and software that provide previously unavailable data, imaging, analytics, and automation for cell culture, stem cell culture, and tissue culture for use in biomedical research and cell therapeutics. Thrive is selling the CellAssist and the CellAssist 50. Both collect 1,000’s of images of live cells in culture, analyzes them, and builds a centralized database. The CellAssist 50 enables researchers to automatically and remotely image 50 plates of cells, generating large amounts of data for live cell biology. Sites include Harvard Stem Cell Institute, Center for Genomic Medicine (Massachusetts General Hospital), Stanford Stem Cell Core, University of Texas Medical Branch, the Broad Institute as well as large and small pharma/biotech companies. Thrive has raised $25M to-date, has 64 patent applications (of which 14 have issued), has an experienced management team and Board with many significant exits, and has 17 employees.
We are a therapeutics startup that has developed the leading “practical cure project” for type 1 diabetes and other autoimmune diseases. The Stem Cell Educator Therapy is a novel, in-vitro therapeutic technology that fundamentally “resets” the dysfunctional immune system underlying diabetes and other autoimmune diseases. We’ve completed 10 years of clinical studies in Spain, China, and US with over 200 patients ranging from 3 to 70 years old. 70% of type 1 and type 2 diabetic patients demonstrated clinical efficacy with many patients reducing insulin and some becoming insulin independent. Our technology has treated more than 10 autoimmune disease including alopecia, lupus, fibrosis, and scleroderma. We are approved and ready to begin two FDA phase 2 clinical trials for type 1 diabetes and alopecia areata.
Unlearn is using novel AI approaches to create disease progression models for clinical research. By leveraging historical datasets and disease-specific machine-learning models, Unlearn generates Digital Twins, defined as statistically indistinguishable, virtual patients that are matched to actual patients in clinical trials. Incorporating Digital Twins into studies increases confidence, accelerates trial timelines, and enables patient level insights. Digital Twins can be added prospectively, enabling smaller, more efficient trials, or retrospectively, adding power to ongoing trials. Digital Twins are currently part of an ongoing pivotal Alzheimer’s Disease trial. Unlearn continues to have discussions with industry leaders and regulators, including the FDA, and is seeking partners to help drive innovation in clinical research using AI. In 2020, Unlearn was named a CB Insights Digital Health 150 Company, and the winner of the Innovation Showcase at CNS Summit.
EDP Biotech develops and commercializes convenient, cost-effective diagnostics which detect disease early.
GRIP Molecular’s single-use biosensor and mobile app provides consumers highly accurate and comprehensive medical diagnostic information in minutes, anytime and anywhere. The patented, graphene-enabled solid-state electronic platform technology is easy to use and does not require chemical reagents or a separate reader. GRIP’s underlying technology can simultaneously detect the presence of infectious disease pathogens and characterize the host response, including the immune response, to enable information-enabled diagnosis and the rapid application of appropriate therapy. The first product will simultaneously provide diagnostic information for COVID-19, Influenza A/B and other common upper respiratory infections. Proof of concept has been completed and development is underway with initial product launch anticipated in 2023.
Inanovate has developed a patented blood analysis system (the Bio-ID) that improves the cost, accessibility, and accuracy of diagnostic tests. The first application of the Bio-ID is a new blood test to be used as a supplement to mammography to help reduce false positive results in breast cancer screening. Approximately 10% of the 39 million screening mammograms performed annually in the US require follow-up testing to resolve the diagnosis, yet more than 95% of these are ‘false positives’ in which no cancer is detected. The economic cost of false-positive mammograms is ~$4 billion, and >1 million women are exposed to risks associated with subsequent diagnostics. Inanovate seeks to address this issue through a simple, inexpensive blood test, that will provide additional data on a patients cancer risk to help inform clinicians whether follow up procedures are necessary.
A novel first-in-class in vitro cellular immunoassay that identifies sepsis after the first-hour of bloodstream infection. We have developed a patented method and kit (with disposable) to identify immune activity biomarkers, that is 3x more sensitive than the current biomarker competitor (PCT) and provides a 10x faster diagnosis than pathogen identification. Our biomarker appears after the first hour of infection, long before PCT can detect the presence of Sepsis. This will allow healthcare professionals to begin accurate treatment earlier – reducing the severity of the disease and decreasing the number of antibiotics or other drugs necessary for treatment.
Patheous Health is building a Dysphagia Care-as-a-Service (CaasSD) business to improve access to feeding and swallow healthcare for senior care providers. Our diagnostic and therapeutic solutions impact patients that suffer from swallowing impairment and nutrition consumption in multiple care settings, including skilled nursing, home health, in-patient rehabilitation, assisted living and community dwelling adults. Patheous Health closed the Series A round in March 2020 and acquired the largest US provider of onsite dysphagia diagnostics. The acquisition provided immediate revenues and 375 senior care provider facility clients. We are building on our customer base, expanding our value-based service, and building a deep channel to introduce our Dysphagic Care-as-a-Service platform. Our team is composed of world-class experts in dysphagia research and care and supported by experienced executives that know how to build a clinical care business.
Virtuleap unlocks neuroscience with virtual reality to help pharmaceutical companies accelerate the approval of drugs designed to treat cognitive illnesses like Alzheimer’s disease.
AthenaX is a digital health platform designed to provide integrated cancer care to underserved patients. By providing rich, real-world data to biotechnology and pharmaceutical companies to increase patient engagement and decrease costs for clinical trials, our cognitive behavioral therapy approach will enable us to care for the whole patient. AthenaX will not only provide virtual supportive cancer care but also create personalized recommendations and serve each patient as their own digital health advocate, particularly for disadvantaged patients with lower socio-economic status, geographical location or lack of equity across racial disparities in healthcare. A key differentiator of our platform will be our partnership with pharmaceutical/biotech companies to customize our platform for their protocols to increase patient engagement, provide greater support and provide real-time monitoring.
care.coach delivers the future of AI, today. Our digital avatars coach the most complex, high risk patients (typically elderly) – 5% of the US population who account for 50% of all healthcare costs — to take better care of themselves and to reduce cost of care for our health insurer customers. Our human-in-the-loop design allows us to surpass the limitations of AI, while training machine learning models to automate and scale human touch in ways that other companies do not have the data for. We are funded by a combined $8 million in private investment and public grants, have published clinical and commercial outcomes, and have closed seven figures in sales revenue. Annualized customer growth rate through 2020 is 3.3x, and existing customers include some of the leading health insurers in the US. We are interested in hiring talented engineers and engaging with Series A investors with expertise in healthcare and AI.
On-Demand Training & Communication at the Point of Care Elemeno’s point-of-care safety solution helps healthcare systems drive consistency of practice at the frontlines, improving patient outcomes at scale, while lowering costs. Elemeno delivers bite-sized team communication and training– updates, decision guides, checklists, and video– to your frontline staff’s fingertips. Content is actionable and trackable, anytime, anywhere. Staff can access Elemeno on any device, desktop, or mobile. We can launch a custom Elemeno application within hours, so clients can standardize care across their system and share best practices from peer institutions coast-to-coast. We have published results and proven ROI (>10x), including decreased hospital infections, happier staff, and reduced labor costs. 48% reduction hospital IV infection reduction & $1MM savings (AJMQ 2018) 75% reduction in serious patient harm events (Ped Qual Safety 2020) 140% increase in staff training participation (AWOHNN 2020) Simple to start. B2B SaaS. No PHI. No IT needed.
Trusted, intelligent tele-dermatology SaaS platform for millions of patients and their doctors.
MiResource helps connect people to the right mental healthcare for their unique needs.
Stellar Health is a healthcare technology company that helps providers and health insurance companies improve quality and financial performance by prompting providers and their practice staff with recommended value-based actions and real-time payments at the point of care. The Stellar Health Platform is a proprietary web-based tool that delivers targeted recommendations designed to meet the new objectives of value-based care delivery models.
Firstlook AI is a healthcare information technology solution that saves providers and payors time and money for claims processing using a novel artificial intelligence system.
Huoleti is a digital transformation company working in health care, particularly working with home and health care companies to provide them better outcomes, customer retention and data driven customer service. For pharmaceuticals it is a key part of their patient support solutions. Kindfull transforms Service Providers to Community Providers. They get plenty of tools to reach their customers and become the center of the community. They can provide care beyond medical care and tune their service portfolio based on service data. As a user service, Kindfull provides unique, hassle-free, multi-channel way to organize help on an on-demand basis. It keeps people in all ages and in all conditions connected to their community.
Addressing the friction around digital health adoption, Marché Health is creating a trusted, independent digital health marketplace that infuses data with community engagement to educate, connect and empower individual stakeholders. Marché aligns business intelligence and decision makers from organizations across healthcare, including health systems, technology, group purchasing, payers and biopharma. This helps facilitate the adoption of value-based healthcare, lower acquisition costs and improve outcomes for patients.
We deliver highly efficient and personalized remote behavioral change programs combining VR, Mindfulness and Psychotherapy, directly from home.
Oshi Health is a virtual clinic that diagnoses and provide whole person treatment for gastrointestinal (GI) conditions. We redesigned GI care from the ground up to be patient-centered, telehealth-first and value-based. Our integrated, GI-specialized care team includes physicians, NPs, dietitians, psychologists and health coaches to help patients implement a personalized care plan to get control of symptoms, improve quality of life and workplace productivity and reduce overall healthcare cost.
Pops offers a consumer centric solution for self-management of diabetes. Pops’ app-based, personalized, AI virtual coach, paired with a smart-glucose meter provides people living with diabetes an option that is easy to use, discreet and supports successful measuring and monitoring of blood sugar while living an active life. Our virtual coach, Mina, engages with our own Rebel glucose meter, simplifying our user’s ability to better manage and direct their health and clinical care needs, increasing accountability toward true behavior change. Pops supports the whole person with sensitivity, meaningful education and guidance. Pops broadens connectivity and data sharing with loved ones and providers. With streamlined connectivity, trend reports and feedback from Mina interactions, Pops consumes fewer Provider resources while enhancing clinical engagement and follow up care. Delivering improved outcomes and supporting healthy lifestyles Pops brings an innovative cost saving solution for employees and their dependents, health plan members and the healthcare ecosystem.
Advanced Surgical Retractors, Inc. is dedicated to the design, development, and commercialization of innovative surgical retractor systems. Surgical retractor systems available today present various limitations, and surgeons are often forced to choose between rapid deployment and optimal exposure. ASR Systems has developed a novel surgical retractor which combines speed and functionality, resulting in improved overall performance.
CathBuddy, Inc. is developing a reusable intermittent catheter system to improve quality of life and the clinical standard of care for individuals with neurogenic bladder. The patented system will also help reduce the environmental waste generated by intermittent catheterization by 84 million pounds annually.
Indago is a biomedical company dedicated to improving the health of patients and addressing the needs of surgeons by introducing transformative products into the operating room. When launched, our first product, ArthroFree, will be the first wireless surgical camera system for use in minimally invasive surgery. Today, the state-of-the-art surgical cameras used in minimally invasive surgeries require long and cumbersome light and power cables, the use of which leads to unnecessary safety risks for patients and medical staff. ArthroFree is designed to replace current surgical cameras while being plug-and-play compatible with current operating room equipment. We anticipate receipt of FDA marketing approval in or around Q4 2021. Our second product, which is in early stages of development, will leverage the patented lighting technology that we developed for ArthroFree and enable better surgical outcomes by bringing wireless and thermally safe lighting to locations in the surgical field where it is needed.
Leviticus Cardio’s wireless power transfer technology, Coplanar Energy Transfer (CET), combined with an existing Ventricular Assist system, provides a new, robust, comprehensive hybrid solution for CHF patients. Leviticus FiVAD™ is wirelessly charged using an external belt along with an internal battery that lasts 6-8 .hours. Patients may expect an improved Quality of Life with Leviticus FiVAD™ because they are free from external equipment for many hours per day.
Precision Microwave is developing the next generation of precision, energy-based, medical devices capable of delivering fast, low-cost, safe, and effective minimally invasive treatment for patients with cancer and other chronic medical conditions. Our current focus is commercialization of our patent-ending directional microwave ablation (DMWA) applicator technology, which we have extensively developed through the support of National Science Foundation SBIR/STTR Phase I & II grants. We are currently heavily involved in coordinating activities with clinical expert advisors, OEMs, regulatory and quality consultants, engineering design firms, academic research partners, sales and marketing consultants, and patent attorneys to bring to market a complete, FDA-cleared, modern MWA system capable of disrupting the minimally invasive treatment market.
The first moments of a newborn’s life are critical to their development but with jaundice affecting over 60% of all babies born each year these important first moments often get interrupted. TheraB Medical is a medical device company that promotes holistic jaundice treatment by keeping babies in the arms of their mother during treatment. The company is commercializing its first product, SnugLit— the only portable, wearable treatment for infant jaundice that promotes maternal-infant bonding and breastfeeding. With SnugLit, newborns will be able to undergo phototherapy using a single, easy-to-use device that covers the entire circumference of the child, as opposed to the current method of using multiple immobile devices simultaneously. SnugLit’s patented design has been developed with over 200 nurses, physicians, and parents to lead to easy and efficient treatment, in both the hospital and home.
